SEP-479 clears first pharmacokinetic hurdle in pursuit of oral hypoparathyroidism therapy
SEP-479 shows a 3-to-4-day half-life in Phase 1, supporting once-daily oral dosing. See what Septerna must prove next in hypoparathyroidism.
Pharma & Biotech